Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 25, 2026, 5:37 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 36 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Pioglitazone HCl Tablets 45 mg Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

Fasting Study of Pioglitazone HCl Tablets 45 mg and Actos® Tablets 45 mg

NCT00649558
View directory record Official record
Conditions
Healthy
Interventions
Pioglitazone HCl Tablets 45 mg, Actos® Tablets 45 mg
Drug
Lead sponsor
Mylan Pharmaceuticals Inc
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Apr 23, 2024 · Synced Sep 25, 2026, 5:37 PM EDT
Completed Phase 3 Interventional Results available

PPAR-gamma Agonists, Rheumatoid Arthritis and Cardiovascular Disease

NCT00554853
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
pioglitazone, Sublingual nitroglycerine
Drug
Lead sponsor
University of Michigan
Other
Eligibility
21 Years to 100 Years
Enrollment
143 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Feb 1, 2017 · Synced Sep 25, 2026, 5:37 PM EDT
Completed Phase 2 Interventional Results available

Pilot Study of Pioglitazone for the Treatment of Moderate to Severe Asthma in Obese Asthmatics

NCT00634036
View directory record Official record
Conditions
Asthma
Interventions
pioglitazone, placebo
Drug
Lead sponsor
Fernando Holguin
Other
Eligibility
18 Years to 60 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
2
States / cities
Pittsburgh, Pennsylvania • Colchester, Vermont
Source: ClinicalTrials.gov public record
Updated Jul 18, 2017 · Synced Sep 25, 2026, 5:37 PM EDT
Completed Phase 4 Interventional Results available

Efficacy of Pioglitazone on Bone Metabolism in Postmenopausal Women With Impaired Fasting Glucose.

NCT00708175
View directory record Official record
Conditions
Bone Metabolism
Interventions
Pioglitazone, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
Up to 70 Years · Female only
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
34
States / cities
Greenbrae, California • Los Banos, California • San Diego, California + 31 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2012 · Synced Sep 25, 2026, 5:37 PM EDT
Completed Phase 3 Interventional Results available

A Phase 3 Study of BMS-477118 in Combination With Metformin in Subjects With Type 2 Diabetes Who Are Not Controlled With Diet and Exercise

NCT00327015
View directory record Official record
Conditions
Diabetes
Interventions
Saxagliptin, Metformin, Placebo, pioglitazone
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 77 Years
Enrollment
1,306 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
47
States / cities
Concord, California • Encinitas, California • Orange, California + 38 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2015 · Synced Sep 25, 2026, 5:37 PM EDT
Completed Phase 3 Interventional Results available

Efficacy of Alogliptin and Pioglitazone in Subjects With Type 2 Diabetes Mellitus

NCT00432276
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
Alogliptin, Pioglitazone, Metformin, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 80 Years
Enrollment
803 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
86
States / cities
Birmingham, Alabama • Huntsville, Alabama • Lake Havasu City, Arizona + 83 more
Source: ClinicalTrials.gov public record
Updated Apr 3, 2013 · Synced Sep 25, 2026, 5:37 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Alogliptin Combined With Pioglitazone in Treating Subjects With Type 2 Diabetes Mellitus.

NCT00328627
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Alogliptin, Alogliptin placebo, Pioglitazone, Pioglitazone placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 80 Years
Enrollment
1,554 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
72
States / cities
Birmingham, Alabama • Columbiana, Alabama • Huntsville, Alabama + 69 more
Source: ClinicalTrials.gov public record
Updated Apr 3, 2013 · Synced Sep 25, 2026, 5:37 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Pioglitazone Treatment for Hyperglycemic Acute Ischemic Stroke

NCT04123067
View directory record Official record
Conditions
Stroke, Acute, Hyperglycemia, Diabetes
Interventions
Pioglitazone 45 mg, Placebo oral tablet
Drug
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
21 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 14, 2022 · Synced Sep 25, 2026, 5:37 PM EDT
Completed Phase 3 Interventional Results available

Actos Now for Prevention of Diabetes (ACT NOW)

NCT00220961
View directory record Official record
Conditions
Impaired Glucose Tolerance, Type 2 Diabetes
Interventions
Pioglitazone, Placebo
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years and older
Enrollment
602 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
8
States / cities
Phoenix, Arizona • Los Angeles, California • San Diego, California + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2016 · Synced Sep 25, 2026, 5:37 PM EDT
Terminated Phase 4 Interventional Results available

Thiazolidinedione Intervention With Vitamin D Evaluation

NCT00879970
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
pioglitazone, rosiglitazone, placebo, Vitamin D, Placebo
Drug · Dietary Supplement
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
50 Years and older
Enrollment
1,332 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
23
States / cities
Long Beach, California • Los Angeles, California • Northridge, California + 19 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2017 · Synced Sep 25, 2026, 5:37 PM EDT
Completed Phase 3 Interventional

Efficacy Study of Pioglitazone and Glimepiride on the Rate of Progression of Atherosclerotic Disease.

NCT00225264
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
Pioglitazone, Glimepiride
Drug
Lead sponsor
Takeda
Industry
Eligibility
45 Years to 85 Years
Enrollment
458 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 27, 2012 · Synced Sep 25, 2026, 5:37 PM EDT
Completed Phase 3 Interventional Results available

Efficacy Study of Pioglitazone Compared to Glimepiride on Coronary Atherosclerotic Disease Progression in Subjects With Type 2 Diabetes Mellitus

NCT00225277
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
Pioglitazone, Glimepiride
Drug
Lead sponsor
Takeda
Industry
Eligibility
35 Years to 85 Years
Enrollment
547 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
65
States / cities
Birmingham, Alabama • Phoenix, Arizona • Huntington Beach, California + 62 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2012 · Synced Sep 25, 2026, 5:37 PM EDT
Terminated Phase 2 Interventional Results available

Pilot Study of Pioglitazone for the Treatment of Moderate to Severe Asthma in Obese Asthmatics (Glitz Asthma)

NCT00787644
View directory record Official record
Conditions
Asthma, Obesity
Interventions
Pioglitazone, Placebo
Drug
Lead sponsor
University of Vermont
Other
Eligibility
18 Years to 60 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Colchester, Vermont
Source: ClinicalTrials.gov public record
Updated Feb 25, 2015 · Synced Sep 25, 2026, 5:37 PM EDT
Completed Not applicable Interventional Results available

Pioglitazone on Pancreatic Steatosis and Bone Health

NCT00855010
View directory record Official record
Conditions
Obesity, Type 2 Diabetes
Interventions
pioglitazone, placebo
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
21 Years to 99 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Dec 12, 2017 · Synced Sep 25, 2026, 5:37 PM EDT
Completed Phase 2 Interventional

Efficacy and Safety of Pioglitazone and Azilsartan in Treating Subjects With Type 2 Diabetes Mellitus

NCT00762736
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
Pioglitazone and azilsartan, Pioglitazone
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
704 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
64
States / cities
Birmingham, Alabama • Huntsville, Alabama • Sierra Vista, Arizona + 61 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2012 · Synced Sep 25, 2026, 5:37 PM EDT
Completed Phase 3 Interventional Results available

Study Assessing Saxagliptin Treatment In Type 2 Diabetic Subjects Who Are Not Controlled With Metformin Alone

NCT00121667
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Saxagliptin + Metformin, Placebo + Metformin, Pioglitazone
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 77 Years
Enrollment
1,462 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
95
States / cities
Anniston, Alabama • Birmingham, Alabama • Calera, Alabama + 92 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2015 · Synced Sep 25, 2026, 5:37 PM EDT
Completed Phase 3 Interventional Results available

30 Week Parallel Group Comparison Study of Linagliptin + Pioglitazone (5+15, 5+30 and 5+45 mg) qd Versus Respective Monotherapies, Followed by a Comparison of 5mg+30mg and 5mg+45mg Versus Respective Monotherapies in Type 2 Diabetes for up to 54 Weeks

NCT01183013
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Pioglitazone 15 mg, Pioglitazone 45 mg, Pioglitazone 30 mg, Linagliptin 5mg / Pioglitazone 45 mg FDC, Linagliptin 5mg / Pioglitazone 30 mg FDC, Linagliptin 5mg, Linagliptin 5mg / Pioglitazone 15 mg FDC
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 80 Years
Enrollment
936 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
74
States / cities
Birmingham, Alabama • Montgomery, Alabama • Muscle Shoals, Alabama + 60 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2014 · Synced Sep 25, 2026, 5:37 PM EDT
Terminated Phase 3 Interventional

Efficacy, Safety and Tolerability of Pioglitazone-Azilsartan in Subjects With Type 2 Diabetes Mellitus

NCT00376181
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Pioglitazone and Azilsartan, Pioglitazone
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
59
States / cities
Huntsville, Alabama • Tallassee, Alabama • Little Rock, Arkansas + 56 more
Source: ClinicalTrials.gov public record
Updated Jun 21, 2010 · Synced Sep 25, 2026, 5:37 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Evaluation of Rosiglitazone Anti-inflammatory Effect With FDG-PET Imaging

NCT01174056
View directory record Official record
Conditions
Lung Inflammation
Interventions
Zileuton, Pioglitazone placebo, Zileuton placebo, Pioglitazone
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
19 Years to 44 Years
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2014
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 22, 2014 · Synced Sep 25, 2026, 5:37 PM EDT
Completed Phase 3 Interventional

Efficacy and Safety of Vildagliptin in Combination With Pioglitazone in Patients With Type 2 Diabetes

NCT00099853
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Vildagliptin, pioglitazone, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 80 Years
Enrollment
362 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 16, 2020 · Synced Sep 25, 2026, 5:37 PM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

Pioglitazone on Heart Failure in Type-2 Diabetes Mellitus Participants

NCT05838287
View directory record Official record
Conditions
Type 2 Diabetes Mellitus in Obese, Heart Failure With Preserved Ejection Fraction
Interventions
Pioglitazone, Placebo
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
30 Years to 70 Years
Enrollment
78 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2030
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Sep 25, 2026, 5:37 PM EDT
Recruiting Phase 2 Interventional

Pioglitazone Versus Empagliflozin for Chronic Pancreatitis/Recurrent Acute Pancreatitis/Acute Pancreatitis Associated Diabetes Mellitus

NCT06729996
View directory record Official record
Conditions
Pancreatitis, Chronic, Pancreatitis, Acute, Diabetes Mellitus
Interventions
Pioglitazone (PIO), Empagliflozin (EMPA)
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 80 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
3
States / cities
Rochester, Minnesota • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Sep 25, 2026, 5:37 PM EDT
Completed Phase 4 Interventional Results available

Pathogenesis of Uric Acid Nephrolithiasis: Role of Pioglitazone/Weight Loss

NCT04370093
View directory record Official record
Conditions
Nephrolithiasis, Uric Acid
Interventions
Pioglitazone 45 mg, Weight Loss, Pioglitazone + Weight Loss
Drug · Behavioral · Other
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
21 Years to 99 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Aug 30, 2026 · Synced Sep 25, 2026, 5:37 PM EDT
Completed Phase 3 Interventional Results available

A Study Assessing Saxagliptin Treatment in Type 2 Diabetic Subjects Who Are Not Controlled With TZD Therapy Alone

NCT00295633
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Saxagliptin, Placebo, pioglitazone, rosiglitazone, metformin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 77 Years
Enrollment
565 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
79
States / cities
Haleyville, Alabama • Mobile, Alabama • Ozark, Alabama + 69 more
Source: ClinicalTrials.gov public record
Updated Apr 6, 2015 · Synced Sep 25, 2026, 5:37 PM EDT